Perlmutter Cancer Center Highlights 2019–2020
Trial provides new options for bacillus Calmette-Guérin–unresponsive non-muscle invasive type.
Four promising projects aim to discover which patients will experience benefits or toxicity.
Perlmutter Cancer Center Highlights, Perlmutter Cancer Center Highlights 2019–2020
These phase 2 trials provide new options for treating glioblastomas and meningiomas.
Dozens of trials explore a wide variety of drug strategies and tumor types.
New programs are changing how individuals are screened for genetic risk for cancer.
Studies show decreases in postoperative morbidity, pain, and recovery time compared with thoracotomy.
Clinicians, researchers, and patients work together to increase 5-year survival rate to 50 percent.
Download Print Version (PDF)
We can help you find a doctor.
browse our specialists.